Premium
Bupivacaine (Marcaine®): An Evaluation of its Tissue and Systemic Toxicity in Humans
Author(s) -
Moore D. C.,
Mather L. E.,
Bridenbaugh L. D.,
Thompson G. E.,
Balfour R. I.,
Lysons D. F.,
Horton W. G.
Publication year - 1977
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1977.tb01201.x
Subject(s) - medicine , bupivacaine , dose , epinephrine , anesthesia , local anesthetic , toxicity , anesthetic , pharmacology
In countries other than the U.S.A., dosages of bupivacaine have been limited to 100 mg without epinephrine and 150 mg with epinephrine. A review of 7,688 regional block procedures employing bupivacaine in concentrations of 0.25, 0.5, and 0.75%, and in dosages as high as 600 mg, indicated that such stringent restrictions: (1) are unwarranted, (2) make comparisons with other local anesthetic agents difficult, and (3) are in need of revision.